Abstract:Background: Targeting MDM2-p53 interaction has emerged as a promising antitumour therapeutic strategy. Certain MDM2-p53 binding inhibitors have advanced into clinical trials; however, the results are not favorable. The lack of specific biomarkers for selecting patients has been assumed as the critical reason for this failure. We have previously found that ZER6 isoform p52-ZER6 is a negative regulator of p53 that enhances p53 ubiquitination/proteasomal degradation; however, whether it could be used as a marker for MDM2-p53 binding inhibitors remain elusive. Methods: The effects of p52-ZER6 on p53 protein accumulation and MDM2/p53 binding capacity were determined using molecular biology and biochemical methods. Cell viability, proliferation potential, and apoptotic rate were determined to examine the p52-ZER6-dependent antagonistic effect as well as p52-ZER6 silencing-dependent agonistic effect on tumour cells sensitivity against MDM2-p53 binding inhibitors. Animal experiment was performed to explore the potential of antitumour combinatorial therapy using p52-ZER6 suppression and these inhibitors in vivo. Findings: p52-ZER6 significantly downregulated tumour cells sensitivity against MDM2-p53 binding inhibitors and attenuated their antitumour effects by strengthening the binding between MDM2 and p53, thus suppresses p53 protein accumulation. p52-ZER6 inhibition enhanced tumour cells sensitivity against these inhibitors by enhancing p53 protein accumulation. Animal experiment results showed that combination of p52-ZER6 inhibition with MDM2-p53 binding inhibitor exerts synergistic antitumour therapeutic effect in vivo. Interpretation: Our results highlight the potential applicability of p52-ZER6 as a therapeutic biomarker for MDM2-p53 binding inhibition-based antitumour therapy, as well as the potential of combining p52-ZER6 antagonist and MDM2-p53 binding inhibitors as a novel antitumour therapeutic strategy.Funding Information: This study was supported by grants from the National Natural Science Foundation of China (31871367, 81872273, 32070715, 82173029); and the Natural Science Foundation of Chongqing (cstc2018jcyjAX0411 and cstc2018jcyjAX0374). Declaration of Interests: Patents related to the results of this study had been filed with Chinese patent application (Nos. 201910626899.0 and 201910626900.X). The authors declare no conflict of interest.Ethics Approval Statement: Animal study was approved by the Institutional Ethics Committee of Chongqing University Cancer Hospital and carried out at Chongqing University Cancer Hospital. All animal experiments conformed to the approved guidelines of the Animal Care and Use Committee of the Chongqing University Cancer Hospital.

Zinc-finger Protein P52-Zer6 Accelerates Colorectal Cancer Cell Proliferation and Tumour Progression Through Promoting P53 Ubiquitination.

Abstract 830: ZFP14, a p53 target, suppresses tumor formation by regulating HOXA gene cluster expression

P52-Zer6: a Determinant of Tumor Cell Sensitivity to MDM2-p53 Binding Inhibitors

The P52-Zer6/g6pd Axis Alters Aerobic Glycolysis and Promotes Tumor Progression by Activating the Pentose Phosphate Pathway.

The E3 Ligase Ring1 Targets P53 For Degradation And Promotes Cancer Cell Proliferation And Survival

p52-ZER6/IGF1R axis maintains cancer stem cell population to promote cancer progression by enhancing pro-survival mitophagy

Identification of ZER6 Isoform P52-Zer6 As an Antitumour Therapeutic Response Determinant for MDM2-p53 Binding Inhibitors

Zeb1-Induced Tumourigenesis Requires Senescence Inhibition Via Activation of Dkk1/Mutant P53/Mdm2/Ctbp and Repression of Macroh2a1

Pharmacological Activation of the P53 Pathway by a New Compound CYZ2017 Exerts Anti-Tumor Effects

Mutant P53 Induces EZH2 Expression and Promotes Epithelial-Mesenchymal Transition by Disrupting P68-Drosha Complex Assembly and Attenuating Mir-26A Processing

ZNF500 Suppresses the Proliferation of Breast Cancer Cells and Sensitizes Them to Chemotherapy by Stabilizing P53 in a Manner That is Competitive to MDM2

ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation

Mice Deficient in the RNA-Binding Protein Zfp871 Are Prone to Early Death and Steatohepatitis in Part through the p53-Mdm2 Axis

p66 Suppresses Breast Cancer Cell Growth and Migration by Acting as Co-Activator of p53

Single-cell Transcriptomic Profiling of Non-Hematopoietic Circulating Cells in Mid-Gestational Mouse Embryos.

The P53 Protein Is A Novel Substrate Of Ribosomal S6 Kinase 2 And A Critical Intermediary For Ribosomal S6 Kinase 2 And Histone H3 Interaction

Mutant p53 improves cancer cells’ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6

Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants

USP53 Affects the Proliferation and Apoptosis of Breast Cancer Cells by Regulating the Ubiquitination Level of ZMYND11

A role for p53 in the regulation of extracellular matrix metalloproteinase inducer in human cancer cells.

Cancer Cells Escape P53's Tumor Suppression Through Ablation of ZDHHC1-mediated P53 Palmitoylation